Data / Form D filings / Unravel Biosciences, Inc.
Unravel Biosciences, Inc.: Form D filings
Unravel Biosciences, Inc., a biotechnology company in Medford, MA, filed 3 Form D notices with the SEC between 2021 and 2026. The latest, on August 24, 2026, reports $4.1 million sold of a $4.5 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 196 BOSTON AVE., SUITE 1000, Medford, MA, 02155
- Phone
- (510) 984-2317
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1876967
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | New notice | $4,500,000 | $4,100,000 | $400,000 | 2 | Aug 7, 2026 | sec.gov |
| Mar 9, 2023 | New notice | $2,000,000 | $500,000 | $1,500,000 | 4 | Feb 22, 2023 | sec.gov |
| Aug 6, 2021 | New notice | $1,000,000 | $500,000 | $500,000 | 3 | Jul 23, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Richard Novak | Executive Officer, Director | |
| Frederic Vigneault | Director | |
| Donald Ingber | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Aug 24, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Unravel Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.